An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
ÎçÒ¹¸£Àû1000¼¯ºÏ
Smart underwear detects lactose intolerance by tracking your farts
News
Environment
2026 will be the hottest year on record, leading scientist predicts
News
Technology
NHS England rushes to hide software over AI hacking fears
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
The 4 biggest myths about hydration, according to an expert
Comment
Popular articles
Trending New Scientist articles
1
Human heads have changed shape a lot in the past 100 years
2
The 4 biggest myths about hydration, according to an expert
3
Is consciousness more fundamental to reality than quantum physics?
4
We have figured out a new way to send messages into the past
5
Weird 'transdimensional' state of matter is neither 2D nor 3D
6
The rings of Uranus are even stranger than we thought
7
NHS England rushes to hide software over AI hacking fears
8
100-year-old assumption about the universe may soon be overturned
9
Why dinosaurs lived much more complex lives than we thought
10
Smart underwear detects lactose intolerance by tracking your farts
